Skip Navigation

This Article
Right arrow Full Text (PDF )
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Klijn, J.G.M.
Right arrow Articles by Foekens, J.A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Klijn, J.G.M.
Right arrow Articles by Foekens, J.A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 9, No. suppl_1, pp. 181-189, 1994
© 1994 European Society of Human Reproduction and Embryology

Pre-clinical and clinical treatment of breast cancer with antiprogestins

J.G.M. Klijn1, B. Setyono-Han1, H.J. Sander1, S.W.J. Lamberts2, F.H. de Jong2, G.H. Deckers3 and J.A. Foekens1

1 Division of Endocrine Oncology, Department of Medical Oncology, Rotterdam Cancer Institute/Dr. Daniel den Hoed Cancer Center Groene Hilledijk 301, 3075 EA Rotterdam 2 Department of Internal Medicine III and Endocrinology, Erasmus University Rotterdam 3 Organon Scientific Development Group, Oss The Netherlands

Antiprogestins form a new potential treatment modality for breast cancer and their mode of action has been assessed in vitro on several breast cancer cell lines, in vivo in rats with diinethylbenz anthracene (DMBA)-induced mammary tumours and in vivo in patients with metastatic breast cancer. In vitro in serum-free medium, the progestin Org 2058 and antiprogestins RU486 and Org 31710 caused a dose-dependently stimulated MCF7 cell growth. Both antiprogestins dose-dependently inhibited the oestrogen-stimulated proliferation of progesterone receptor (PgR)-rich T-47D cells in DCC medium. Inhibition by Org 31710 plateaued at 10–8 M (74% inhibition), compared with RU486 at up to 10–6 M (53% inhibition). No inhibition was observed at doses of 10–12–10–6 M of both antiprogestins in the absence of oestradiol . The proliferation of the ZR-75.1 and MDA-MB-231 cell lines was not or only marginally affected by either antiprogestin. Rats with DMBA-induced mammary tumours given prophylactic treatment with RU486 displayed a doubted latency period. Antiprogestins were slightly more effective than tamoxifen or progestins in rats with existing tumours. Org 31710 sometimes showed a somewhat more pronounced inhibitory effect than the antiprogestins Org 31806 and RU486. Combined antiprogestational and anti-oestrogenic treatment showed striking additive growth inhibitory effects resulting in clear tumour remissions, in the presence of very strong suppression of oestrogen and PgRs. The growth inhibitory effect of luteinizing hormone-releasing hormone agonists was potentiated by antiprogestins. A preliminary dinical study on the efficacy of second-line treatment with RU486 in 11 post-menopausal patients with breast cancer yielded one objective response and six instances of short-term stable disease. Two clinical studies using RU486 as second or third-line treatment reported a partial response in 12% and stable disease in 46% among 33 patients, especially those with PgR-positive primary tumours. However, clear anti-glucocorticoid endocrine and clinical side-effects resulted in very high adrenocorticotrophic hormone, androstenedione and cortisol concentrations and peripheral aromatization of adrenal-derived androgens raised plasma oestradiol concentrations. Antiprogestins clearly cause growth inhibitory effects on oestradiol-stimulated PgR-rich tumour cell lines, rat mammary tumours and in patients with metastatic breast cancer.

Key words: antiprogestin/breast cancer/clinical/pre-clinical/treatment


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Endocr Relat CancerHome page
C. Lanari, C. A Lamb, V. T Fabris, L. A Helguero, R. Soldati, M. C. Bottino, S. Giulianelli, J. P. Cerliani, V. Wargon, and A. Molinolo
The MPA mouse breast cancer model: evidence for a role of progesterone receptors in breast cancer
Endocr. Relat. Cancer, June 1, 2009; 16(2): 333 - 350.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.